EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy

Sumit Saha iD, Xianjun Fang, Christopher D Green, Anindita Das iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242015078 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Sumit Saha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Diabetic Cardiomyopathies, Insulin Resistance. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS, BLRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic cardiomyopathy is a critical diabetes-mediated co-morbidity characterized by cardiac dysfunction and heart failure, without predisposing hypertensive or atherosclerotic conditions. Metabolic insulin resistance, promoting hyperglycemia and hyperlipidemia, is the primary cause of diabetes-related disorders, but ambiguous tissue-specific insulin sensitivity has shed light on the importance of identifying a unified target paradigm for both the glycemic and non-glycemic context of type 2 diabetes (T2D). Several studies have indicated hyperactivation of the mammalian target of rapamycin (mTOR), specifically complex 1 (mTORC1), as a critical mediator of T2D pathophysiology by promoting insulin resistance, hyperlipidemia, inflammation, vasoconstriction, and stress. Moreover, mTORC1 inhibitors like rapamycin and their analogs have shown significant benefits in diabetes and related cardiac dysfunction. Recently, FDA-approved anti-hyperglycemic sodium–glucose co-transporter 2 inhibitors (SGLT2is) have gained therapeutic popularity for T2D and diabetic cardiomyopathy, even acknowledging the absence of SGLT2 channels in the heart. Recent studies have proposed SGLT2-independent drug mechanisms to ascertain their cardioprotective benefits by regulating sodium homeostasis and mimicking energy deprivation. In this review, we systematically discuss the role of mTORC1 as a unified, eminent target to treat T2D-mediated cardiac dysfunction and scrutinize whether SGLT2is can target mTORC1 signaling to benefit patients with diabetic cardiomyopathy. Further studies are warranted to establish the underlying cardioprotective mechanisms of SGLT2is under diabetic conditions, with selective inhibition of cardiac mTORC1 but the concomitant activation of mTORC2 (mTOR complex 2) signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsDiabetic CardiomyopathiesInsulin ResistanceHyperlipidemiasHumansMechanistic Target of Rapamycin Complex 1Sodium-Glucose Transporter 2Mechanistic Target of Rapamycin Complex 2Sodium

Stichwörter der Autor:innen

AMPKSGLT2idiabetesdiabetic cardiomyopathymTORC1/2

Substanzen

Sodium-Glucose Transporter 2 InhibitorsMechanistic Target of Rapamycin Complex 1Sodium-Glucose Transporter 2Mechanistic Target of Rapamycin Complex 2Sodium

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Division of Cardiology, Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.

ORCID-Profile: Sumit Saha, Anindita Das

Förderung

  • NHLBI NIH HHS
  • NCI NIH HHS
  • BLRD VA
  • NIH HHS
  • National Institutes of Health
  • Astar Biotech Research Award
  • VA Merit Award

Zitieren

APA

Saha, S., Fang, X., Green, C. D., & Das, A. (2023). mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242015078

Vancouver

Saha S, Fang X, Green CD, Das A. mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242015078

BibTeX
@article{Saha2023,
  author = {Saha, Sumit and Fang, Xianjun and Green, Christopher D and Das, Anindita},
  title = {mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242015078}
}
Kostenlos starten →